Aroda VR, Aberle J, Bardtrum L, Christiansen E, et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Lancet 2023 Jun 23:S0140-6736(23)01127-3. doi: 10.1016/S0140-6736(23)01127.
PMID: 37385279